Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01342367 · ClinicalTrials.gov registry record · NA

Feasibility of Hormones and Radiation for Intermediate or High Risk Prostate Cancer

A NA study of Prostate Cancer, sponsored by University of Chicago.

Active
Registry status
NA
Development phase
74
Enrollment target
1
Study location

NCT01342367 is a NA study of Prostate Cancer that is active but no longer recruiting, run by University of Chicago. The registered enrollment target is 74 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01342367, a NA study of Prostate Cancer, is active but no longer recruiting, sponsored by University of Chicago.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
74 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is see if quality of life is improved in patients receiving oral hormone therapy compared to standard of care. The study will also compare survival rates between patients receiving oral hormone therapy and those receiving standard of care.

Conditions Studied

Interventions

  • RADIATION Radiation
  • DRUG Finasteride
  • DRUG Bicalutamide
  • DRUG Dutasteride

Study Locations (1)

Illinois

  • University of Chicago - Chicago

Trial Details

FieldValue
Enrollment Target 74 participants
Start Date 2010-12-17
Est. Completion 2026-02
Phase NA

Sponsor

University of Chicago

796 total trials

What the Registry Record Tells You About NCT01342367

The ClinicalTrials.gov registry entry for NCT01342367 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 74 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (88% lower). The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 4 interventions - of which Radiation is the first listed.

NCT01342367 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.

Frequently Asked Questions

What is clinical trial NCT01342367 about?

NCT01342367 is a clinical study titled "Feasibility of Hormones and Radiation for Intermediate or High Risk Prostate Cancer". The purpose of this study is see if quality of life is improved in patients receiving oral hormone therapy compared to standard of care. The study will also compare survival rates between patients receiving oral hormone therapy and those receiving standard of care.

What is the current status of trial NCT01342367?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 74 participants. The study started on 2010-12-17. Estimated completion is 2026-02.

What conditions does trial NCT01342367 study?

This clinical trial studies the following conditions: Prostate Cancer.

What interventions are being tested in trial NCT01342367?

The interventions under investigation include: Radiation (RADIATION), Finasteride (DRUG), Bicalutamide (DRUG), Dutasteride (DRUG).

Who is sponsoring clinical trial NCT01342367?

This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01342367 being conducted?

This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.